Sarepta Therapeutics, Inc. $SRPT Holdings Trimmed by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.1% during the 4th quarter, HoldingsChannel reports. The firm owned 727,786 shares of the biotechnology company’s stock after selling 1,053,562 shares during the quarter. BNP Paribas Financial Markets’ holdings in Sarepta Therapeutics were worth $15,662,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. iSAM Funds UK Ltd purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $25,000. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Sarepta Therapeutics by 82.5% during the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 851 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SRPT. Oppenheimer restated an “outperform” rating and set a $37.00 price target on shares of Sarepta Therapeutics in a report on Thursday, March 19th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company lowered their price target on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Finally, Wedbush upped their price objective on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 26th. Eight research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $24.77.

Sarepta Therapeutics Trading Down 5.5%

Shares of NASDAQ:SRPT opened at $15.75 on Friday. The stock has a market capitalization of $1.66 billion, a PE ratio of -16.41, a P/E/G ratio of 0.17 and a beta of 0.21. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $43.92. The firm has a fifty day moving average price of $19.81 and a 200 day moving average price of $19.81. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($3.42) EPS. Analysts expect that Sarepta Therapeutics, Inc. will post 3.99 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.